URSA - Drugs and Clinicals Solv-2: leaderboard
Metric: Solv-2 solved targets (%; share of the 100 URSA-drugs&clinicals-2026 approved drugs and clinical candidates with stock-terminated routes proposed for those targets whose every reaction also passes the ChemCensor precedent-based plausibility check (Solv-2), best of up to 10 routes per target, URSA-minor-1.1.0-U2 configuration with ChemCensor v1.2.0 and the U2 USPTO precedent database, shared stock of 255,365 building blocks; default reasoning effort; higher is better). Source: arxiv.org. Saturation forecast: Around March 2027. 17 models tracked.
Top models
| # | Model | Score |
|---|---|---|
| 1 | Gemini 3.1 Pro (Preview) | 38 |
| 2 | GPT-5.5 | 35 |
| 3 | Claude Opus 4.8 | 27 |
| 4 | Grok 4.1 | 24 |
| 5 | Claude Opus 4.7 | 22 |
| 6 | Claude Opus 4.5 | 19 |
| 7 | Qwen 3.5 397B A17B | 15 |
| 8 | Claude Opus 4.6 | 14 |
| 9 | Kimi K2.5 | 10 |
| 10 | GLM-5 | 10 |
| 11 | Claude Sonnet 4.6 | 8 |
| 12 | Claude Sonnet 4.5 | 7 |
| 13 | GPT-5.2 | 7 |
| 14 | GPT-5.4 | 6 |
| 15 | DeepSeek V3.2 | 1 |
Interactive version: theaggregate.ai/benchmark?slug=ursa-drugs-and-clinicals-solv-2 · How It Works · Data refreshed daily, snapshot 2026-09-29.